Mitochondria as a therapeutic target for common pathologies.
View / Open Files
Authors
Murphy, Michael P
Hartley, Richard C
Publication Date
2018-12Journal Title
Nature Reviews Drug Discovery
ISSN
1474-1776
Publisher
Springer Nature
Volume
17
Pages
865-886
Language
eng
Type
Article
This Version
AM
Metadata
Show full item recordCitation
Murphy, M. P., & Hartley, R. C. (2018). Mitochondria as a therapeutic target for common pathologies.. Nature Reviews Drug Discovery, 17 865-886. https://doi.org/10.1038/nrd.2018.174
Abstract
Although the development of mitochondrial therapies has largely focused on diseases caused by mutations in mitochondrial DNA or in nuclear genes encoding mitochondrial proteins, it has been found that mitochondrial dysfunction also contributes to the pathology of many common disorders, including neurodegeneration, metabolic disease, heart failure, ischaemia-reperfusion injury and protozoal infections. Mitochondria therefore represent an important drug target for these highly prevalent diseases. Several strategies aimed at therapeutically restoring mitochondrial function are emerging, and a small number of agents have entered clinical trials. This Review discusses the opportunities and challenges faced for the further development of mitochondrial pharmacology for common pathologies.
Keywords
Animals, Clinical Trials as Topic, DNA, Mitochondrial, Humans, Mitochondria, Mitochondrial Diseases, Pharmaceutical Preparations
Sponsorship
Medical Research Council (MC_UU_00015/3)
Wellcome Trust (110159/Z/15/Z)
Medical Research Council (MC_U105663142)
Identifiers
External DOI: https://doi.org/10.1038/nrd.2018.174
This record's URL: https://www.repository.cam.ac.uk/handle/1810/287068
Rights
Licence:
http://www.rioxx.net/licenses/all-rights-reserved
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk